311 related articles for article (PubMed ID: 8946280)
1. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
[TBL] [Abstract][Full Text] [Related]
3. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
4. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
[TBL] [Abstract][Full Text] [Related]
6. Factors determining the ability of cytokine-activated killer cells to lyse human ovarian carcinoma targets.
Hirte HW; Clark DA
Cell Immunol; 1991 Aug; 136(1):122-32. PubMed ID: 2060017
[TBL] [Abstract][Full Text] [Related]
7. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
Zheng YJ; Zhang J; Wang SM; Zhang JR
Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.
Ozkan A; Ayhan A; Fiskin K
Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929
[TBL] [Abstract][Full Text] [Related]
9. [Human LAK cell induction and its biological characteristics].
Wu YY
Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):254-7. PubMed ID: 2125554
[TBL] [Abstract][Full Text] [Related]
10. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.
Odening KE; Li W; Rutz R; Laufs S; Fruehauf S; Fishelson Z; Kirschfink M
Clin Exp Immunol; 2009 Feb; 155(2):239-48. PubMed ID: 19040611
[TBL] [Abstract][Full Text] [Related]
11. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of multidrug-resistant human T-lymphoblastoid CEM cell line to cell-mediated cytolysis.
Ramoni C; Dupuis ML; Cenciarelli C; Ciccolini F; Cianfriglia M
Ann Ist Super Sanita; 1990; 26(3-4):433-9. PubMed ID: 1982604
[TBL] [Abstract][Full Text] [Related]
13. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
15. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
16. Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells.
Treichel RS; Bunuan M; Hahn N; Wee K
Int J Cancer; 2004 Jan; 108(1):78-85. PubMed ID: 14618619
[TBL] [Abstract][Full Text] [Related]
17. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
19. [The enhancement of cytolytic activity in lymphokine activated killer cells using bispecific F(ab')2].
Azuma A
Nihon Ika Daigaku Zasshi; 1991 Dec; 58(6):663-72. PubMed ID: 1663120
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents.
Allavena P; Damia G; Colombo T; Maggioni D; D'Incalci M; Mantovani A
Cell Immunol; 1989 Apr; 120(1):250-8. PubMed ID: 2784721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]